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A Patient Advocate’s Perspective
Andrea M. Williams, BA,1 Kim Smith-Whitley, MD2,3BackgroundImproved health care for children with sickle celldisease has increased the likelihood of survival toyoung adulthood for those born in the U.S. with this
inherited rare disease. However, despite improving pedia-
tric clinical outcomes, challenges remain: Children and
adults have limited access to high-quality health care;
overall survival remains decreased, pain management is
supportive without any disease-speciﬁc pain interventions,
transition to adult care is poorly organized, and develop-
ment of disease-modifying therapies and universally
available cures remains limited. Federal organizations,
healthcare systems, scientiﬁc and medical societies, patient
advocacy organizations, and other prominent stakeholders
in the sickle cell disease community have offered solutions
to these problems but policies to institute change have not
emerged. Many have suggested that if the sickle cell disease
community would unite to focus on advancing a common
agenda, one “voice,” then meaningful change would
result.1,2 The overall concerns of these stakeholders should
not be too disparate. One would imagine that all could
agree to focus on the following goals:1. increasing access to high-quality patient care;
2. developing drugs and therapies to increase survival
and improve quality of life; and
3. ﬁnding cures for sickle cell disease that are relatively
accessible, safe, and with limited long-term com-
plications.
Partnerships must develop among stakeholders in the
sickle cell community, and a uniﬁed voice must emerge
that resoundingly reﬂects the concerns of the patientshildren’s Sickle Cell Foundation, Inc., Pittsburgh, Pennsylva-
rehensive Sickle Cell Center, The Children’s Hospital of
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open access article under the CC BY-NC-ND license (http://cand their families. Focusing on the goal of increasing
access to high-quality patient care, this editorial explores
challenges and solutions from the patient advocacy
organization perspective.
The concept of “access to care” is broad and complex
for those living with chronic illness. Many Americans
with sickle cell disease have socioeconomic challenges
that include living in households with low family
incomes, residing in geographic locations with few sickle
cell disease healthcare experts, attaining and maintaining
health insurance, and trying to lead productive lives with
a chronic medical condition. In addition, racial and
cultural differences between the patient and members
of the healthcare community may exist that impede
effective communication and therapeutic relationships.
Furthermore, the stigma associated with living with sickle
cell disease further isolates children and adults. For these
and other reasons, children and adults with sickle cell
disease may beneﬁt from services provided by sickle cell
disease community-based organizations.
Individuals living with sickle cell disease are likely to
deﬁne high-quality health care similar to the general
population. This deﬁnition would include the idea of
having the best health care available to you when you
need it and having it delivered in a way that provides the
best outcomes. IOM embodies this concept in their six
fundamentals of high-quality health care: safe, timely,
patient-centered, effective, efﬁcient, and equitable. The
body of work presented in this special supplement
addresses many of these fundamentals. The following
provides more-speciﬁc elements on how children and
adults with sickle cell disease should be provided access
to high-quality health care:1.Inc
reatAccess to high-quality care should be universal across a
wide variety of primary care and specialty care settings.2. Systems to monitor quality indicators of care should
be in place across care settings.3. Efforts to improve clinical care for people with sickle cell
disease should address care for adults and children.4. Disease self-management skills should be an element
of high-quality health care across the life span.5. Children and adults with sickle cell disease and their
families should have accessible resources to identify.
ivecommons.org/licenses/by-nc-nd/4.0/).
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advocacy initiatives both nationally and within their
communities.6. Resources to better identify and access sickle cell
disease community-based organizations and advocacy
organizations should be developed.7. The sickle cell disease community should collect and
have access to data that inform healthcare advocacy
initiatives for research, health care, education, and
awareness.8. Funding and policies to support and sustain high-
quality clinical care for children and adults with sickle
cell disease should increase.9. Funding to support innovative science and clinical
research trial participation should be increased.
Access to High-Quality Care
Solutions to broader access must address outpatient,
inpatient, and acute/emergent care. Pain management is
challenging, particularly when emergent care settings are
used. Day hospitals and alternative urgent care may
provide pain management in a setting conducive to
prompt treatment and extended stays until pain can be
managed in an outpatient setting. These day hospitals or
urgent care units may combine resources with other
outpatient settings such as transfusion or infusion units
designed to provide care for oncology patients. Despite
the setting of initial pain management, connecting
patients to their medical home team shortly after acute
illness visits should lead to better outcomes. Putting
teams in place will ensure that prescriptions have been
ﬁlled and treatment plans are being followed. Ensuring
that patients have follow-up appointments within 24
hours and analgesics in hand prior to discharge or shortly
after discharge may increase the likelihood that their
outpatient pain management will be successful, hopefully
leading to reduced readmissions. This type of care
coordination is necessary for patients with sickle cell
disease across the life span. Children and adults have
screening procedures for stroke risk and pulmonary
hypertension that rely on ancillary services. A
community-based organization involved in care coordi-
nation would be best suited to understand the medical
and non-medical needs of the patient and to identify
resources in local communities.
Systems to Monitor Quality Indicators of
Care
Safe, timely care is central to pain management across all
settings but particularly for emergent care. Emergencymedicine healthcare teams must be involved in develop-
ing clinical pathways that emphasize pain relief and
implementing quality indicators such as timing to ﬁrst
analgesic. Inpatient units should pay close attention to
the side effects of analgesics and the development of
acute chest syndrome. These processes should be devel-
oped across care settings and include febrile illness and
neurologic symptom management. Once developed, a
systematic tracking method should allow data sharing to
support quality improvement initiatives. Healthcare
systems should share information with consumers to
allow patients to make informed decisions about where
they receive their health care. This type of monitoring
could be built within the medical home and care network
structure, but their outcomes reporting should include
community-based organizations and patient advocacy
organizations.
Because of the subjective nature of pain and the need
to include patients in its assessment, tension between
patients and their healthcare teams develops when there
is discrepancy between a patient’s desired pain manage-
ment and the plan of their healthcare team. Patients and
their families should be involved in pain management
decisions when appropriate. A patient’s bill of rights has
been helpful in cases where distrust has developed
between patient and care teams. However, patients
should be equally attentive to respectful, positive com-
munication and interaction with health teams. Restoring
trust is typically more difﬁcult, but should be considered
the priority when trust dissipates. Healthcare providers
in all settings should be educated on cultural competency
and conﬂict resolution strategies with a goal of rebuilding
trust. Patient and parent support groups should be
encouraged to include healthcare providers in their
discussions of ways to improve hospital experiences.Care for Adults and Children
Historically, many medical advances in sickle cell disease
research have addressed outcomes more frequently in
children than adults. Infection and stroke prevention has
saved and improved lives of American children with
sickle cell disease. Compare these advances in pediatrics
to those in adult-focused care. The greatest medical
advance in adult-focused care has been related to one
disease-modifying agent, hydroxyurea. However, pain
and acute chest syndrome remain the top causes of
morbidity and mortality in adults with sickle cell disease.
Given the continued early mortality in adulthood and the
low percentage of adults receiving long-term therapies,
new models of care to address access to high-quality care
in adults need to be more expedient.www.ajpmonline.org
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Patients should be empowered with information that
allows them to better identify concerning symptoms and
improve adherence with medication. No patient or
parent of a child with sickle cell disease should leave a
healthcare setting without a better understanding of how
to care for themselves or their child. Patient education
should include resources that go beyond direct commu-
nication with the medical team. Written health education
materials and computer and web-based resources enrich
patient education. Community-based organizations with
expertise in sickle cell disease can make a meaningful
difference by providing information to patients and their
families.
Williams and Smith-Whitley / AAccessible Resources for Advocacy
Initiatives
Community-based organizations that provide useful
resources and services that decrease barriers to care are
critical. However, resources that detail information on
types of provided services, organized in a user-friendly,
readily accessible fashion, are limited. Improved disease
awareness initiatives should communicate these concerns
and foster clinical care improvements, novel disease-
modifying therapies, and cures in a manner that is most
meaningful to patients. Clinical research designs that
support trials that inform probabilities of health out-
comes based on individual patient factors are needed.
Clinical trial endpoints should address complications
that are important to patients, particularly those that
reﬂect quality of life. Disease-speciﬁc quality of life
assessment tools are close to completion and should be
incorporated into clinical care and clinical research.
Without a disease surveillance program, tracking
access to high-quality care and clinical outcomes is
extremely limited. However, the use of large healthcare
information databases to estimate utilization of health-
care services by children and adults with sickle cell
disease could be a solution to better understand variation
in patterns of care. Transition of care from home to acute
care settings as well from pediatric- to adult-focused care
is a major barrier to continuous, high-quality health care
across the life span. A poorly resourced healthcare
workforce expert in the care of patients with sickle cell
disease is a frequently referenced problem in the sickle
cell disease community. When patients are coming from
home to emergency departments for urgent/emergent
health issues, they are often reluctant as they worry about
their ability to get culturally competent, compassionate,
safe, and high-quality care in these settings. Ultimately,
they are concerned that they are not receiving care from aJuly 2016healthcare provider knowledgeable about their sickle cell
disease. Ensuring effective communication between their
primary healthcare team and emergency care teams
about their accurate health information may resolve
some of these issues. For those that do not have a
primary care team or a medical home, systems should be
developed to connect them to one. Partnerships with
healthcare systems and community-based organizations
should be developed to address this issue.
Even when adult care–focused providers are available,
transition from pediatric- to adult-focused health care is
challenging. The role of the parent and pediatric team is
critical. Limiting their participation and control over the
process is difﬁcult and problematic. Health system issues
are challenging to navigate even for those without
chronic illness and abundant resources. Understanding
the concerns of patients and their families, healthcare
providers, and leaders in health systems communities
should be instrumental in ﬁnding solutions. Health
information technology is an important resource that
could be incorporated into transition programs from
both the provider and patient perspectives. Using elec-
tronic health records to share information between
pediatric and adult care providers and allowing both
providers to track outcome measures of successful
transition should be considered.
Access to Community-Based Organizations
Enlisting the services of community-based organizations
could clearly improve access to health care that may be
limited because of a patient’s poor understanding regard-
ing the need for a variety of healthcare providers,
difﬁculties with transportation to care centers, problems
with maintaining health insurance and navigating com-
plex healthcare systems, and difﬁculty in communicating
with healthcare teams and poor adherence to medication.
Understanding the strengths of individual community-
based organizations and focusing on methods to improve
resources, develop new programs, and sustain positive
outcomes through continued funding is critical to estab-
lishing quality measures for all community-based orga-
nizations. For example, if relationships between hospitals
and community-based organizations are fostered at both
the pediatric and adult levels, then transitions of care
may be improved by using the local community-based
organization as a backbone to reinforce patient educa-
tion, facilitate care coordination, and address barriers to
successful school and work performance at the individual
level. Behavioral health problems in the sickle cell
disease community are under-recognized and subse-
quently poorly treated. Bringing assessment tools on
quality of life into the sickle cell community may
Williams and Smith-Whitley / Am J Prev Med 2016;51(1S1):S5–S9S8be a method of screening for high-risk features for
behavioral health issues. Increasing awareness of beha-
vioral health issues in the community and identifying
support services through community-based organiza-
tions may decrease the stigma associated with behavioral
health needs.
Access to Data
Owing to variation in services provided by states for
children with sickle cell disease identiﬁed through new-
born screening, the opportunity to track outcomes is not
consistent within and throughout the states. The oppor-
tunities for newborn screening follow-up are numerous
but are plagued with important issues such as health
information privacy, inconsistent coding practices, lack
of data storage, and poor standardization of needed data
elements. Programs for disease surveillance, disease out-
comes tracking, and monitoring access to high-quality
health care would be a worthwhile endeavor and a
natural progression of state newborn screening pro-
grams. With participation of community-based organi-
zations and healthcare systems, the opportunity to track
children and adults with sickle cell disease would be
bolstered. This would allow the collection and analysis of
important data to better inform health policy for those
with sickle cell disease.
Therapies directed at improving quality of life, particu-
larly for adults with sickle cell disease, are needed. Cures
for both children and adults with all genotypes of sickle cell
disease are long overdue. To improve health care for sickle
cell disease, access to high-quality health care throughout
the life span; therapies to improve quality of life and cure
sickle cell disease; education for consumers or patients,
families, and healthcare providers; and awareness in the
communities must be the focus of such efforts. However,
in this context, issues of disparities of care, culturally
sensitive community engagement, healthcare system
complexities, disease stigma, behavioral health issues,
ever-changing health policies, and third-party payer
regulations must be addressed to develop an advocacy
platform that serves all.
High-Quality Clinical Care for Children and
Adults
Access to resources is greatly limited. This has fragmen-
ted the sickle cell disease community. Researchers and
clinical care centers compete for limited federal and
foundation dollars. Patient advocacy and community-
based organizations compete for philanthropic dollars
and private industry sponsorship. Many children and
adults with sickle cell disease live below the poverty lineand require additional support to access and maintain
access to health care. In this environment, it is para-
mount to have consistent and sustainable funding to
support excellence in clinical care, research, and care
coordination services. Legislation is poised to secure
funding, yet despite all efforts, the H.R.1807 Sickle
Cell Disease Research, Surveillance, Prevention, and
Treatment Act 2015 has not been reauthorized.
Sickle cell disease should be excluded under the Read-
missions Reduction Act so that hospitals will be not
be penalized for the care of patients with sickle
cell disease where return to hospitals for management
of febrile illness and unpredictable pain may be unavoid-
able. Policies related to chronic opioid use and medical
marijuana could greatly impact patients living with sickle
cell disease. Patients and patient advocacy organizations
need to be ready to address these issues proactively before
further legislation negatively affects access.
Innovative Science and Clinical Research
Trials
Although advances in medicine have led to improved
outcomes for some, the cure for sickle cell disease and the
sole disease-modifying drug are not available, accessible,
or effective for all patients. To develop new cures
and disease-modifying agents, innovative basic science
and clinical research must be initiated and funded. In
addition to a diminishing healthcare workforce available
to provide high-quality clinical care for adults with sickle
cell disease, many believe that young scientists and
clinical investigators are losing interest in hematology.
Programs developed to improve resources and access to
mentors in science, technology, engineering, and math
areas could resolve this issue. On the patient side,
increased clinical trial participation is needed. However,
reasons for slow, limited clinical trial participant
recruitment are unknown. Though some suggest that
mistrust plays a key role,3 poor resources are available to
support clinical trial participants who may have limited
socioeconomic resources and whose disease or treat-
ments may limit their ability to fully participate. Further
investigation is needed to appropriately address the
barriers to clinical trial participation from both the view
of the patient and that of the healthcare system and
private industry. Concentrating on developing therapies
for outcomes that are meaningful to the sickle cell disease
community is paramount.
Conclusions
Ultimately, many of the concerns of the sickle cell
disease community could be resolved by developing anwww.ajpmonline.org
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patients to the healthcare community, thus allowing
them to identify and access1.Julhealthcare providers in their community who provide
high-quality care for patients with sickle cell disease;2. clinical research projects;
3. advocacy and awareness projects; and
4. psychosocial support services.
This initiative is best supported by a patient advocacy
organization that could secure and maintain funding as
well as stakeholder commitments. Resoundingly, the
stakeholders within the sickle cell disease community
must focus on access to high-quality health care. How-
ever, the interests of children and adults with sickle
cell disease must be prioritized within this context.
For although a uniﬁed message is an important concept
to carry a rare disease–focused agenda forward in termsy 2016of research funding and health policy initiatives, if the
message does not reﬂect the concerns and needs of
patients, then that “one voice” will be forever divided.
Publication of this article was supported by the Centers for
Disease Control and Prevention.
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